Home
Research
Basilea
Diurnal Group
About
Services
Contact
Partners
Sign up
Blog
More
Use tab to navigate through the menu items.
All Posts
Search
Brian White
Apr 27
Basilea - Boosting the anti-fungal franchise
bw2078
Apr 25
Diurnal Group - Efmody set for Swiss launch with EffRx
Brian White
Apr 20
Diurnal Group - European commercial roll-out continues
Andrew Keith
Apr 1
Diurnal Group - SMC decision, financial results and outlook
Brian White
Mar 30
Diurnal Group - Commercial rollout continues
Andrew Keith
Mar 10
Basilea - Refocusing on anti-infectives
Brian White
Mar 8
Diurnal Group - SMC decision another hurdle to jump
Brian White
Feb 15
Basilea - Strategic repositioning
Andrew Keith
Feb 14
Diurnal Group - The AI and TRT opportunities
Brian White
Feb 10
Diurnal Group - Efmody moving into larger AI disorder
Brian White
Jan 26
Diurnal Group - Trading update ahead of R&D day
Andrew Keith
Jan 24
Basilea - Phase 2 data on derazantinib at ASCO
Brian White
Jan 13
Basilea - Fleshing out the Chinese Cresemba franchise
Brian White
Jan 11
Basilea - ERADICATE enrolment completed
Brian White
Jan 11
Diurnal business update - much to look forward to
Brian White
Jan 10
Basilea - 2021 trading update provides financial reassurance
Brian White
Jan 7
Basilea - Cresemba milestone provides a strong start to 2022
Brian White
Dec 21, 2021
Basilea - Cresemba's China approval
Brian White
Dec 17, 2021
Basilea - A burgeoning oncology pipeline
Andrew Keith
Dec 14, 2021
Diurnal Group - Efmody 2022
1
2
3
4
